The stock of Conduit Pharmaceuticals Inc (CDT) has gone down by -24.84% for the week, with a -67.06% drop in the past month and a -94.17% drop in the past quarter. The volatility ratio for the week is 13.21%, and the volatility levels for the past 30 days are 23.09% for CDT. The simple moving average for the past 20 days is -34.63% for CDT’s stock, with a -93.49% simple moving average for the past 200 days.
Is It Worth Investing in Conduit Pharmaceuticals Inc (NASDAQ: CDT) Right Now?
Moreover, the 36-month beta value for CDT is 2.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDT is 10.34M and currently, short sellers hold a 5.99% of that float. On August 05, 2024, CDT’s average trading volume was 2.90M shares.
CDT) stock’s latest price update
The stock of Conduit Pharmaceuticals Inc (NASDAQ: CDT) has decreased by -12.90 when compared to last closing price of 0.20. Despite this, the company has experienced a -24.84% fall in its stock price over the last five trading sessions. investorplace.com reported 2024-07-16 that Conduit Pharmaceuticals (NASDAQ: CDT ) stock is taking off on Tuesday alongside a new patent for the clinical-stage specialty biopharmaceutical company. Conduit Pharmaceuticals notes that it now has an Austrailian patent that covers its HK-4 Glucokinase Activator that targets autoimmune diseases.
CDT Trading at -87.00% from the 50-Day Moving Average
After a stumble in the market that brought CDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.30% of loss for the given period.
Volatility was left at 23.09%, however, over the last 30 days, the volatility rate increased by 13.21%, as shares sank -65.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -94.09% lower at present.
During the last 5 trading sessions, CDT fell by -24.80%, which changed the moving average for the period of 200-days by -89.94% in comparison to the 20-day moving average, which settled at $0.2513. In addition, Conduit Pharmaceuticals Inc saw -96.16% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CDT
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.38 for the gross margin
The net margin for Conduit Pharmaceuticals Inc stands at 0.04. The total capital return value is set at 0.02. Equity return is now at value -2.10, with -1.04 for asset returns.
Based on Conduit Pharmaceuticals Inc (CDT), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 1.05. The interest coverage ratio of the stock is -7.51.
Currently, EBITDA for the company is -5.56 million with net debt to EBITDA at 10.13. When we switch over and look at the enterprise to sales, we see a ratio of 0.63. The receivables turnover for the company is 2.87for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.59.
Conclusion
To wrap up, the performance of Conduit Pharmaceuticals Inc (CDT) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
